Squarepoint Ops LLC increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 286.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 149,717 shares of the company's stock after acquiring an additional 110,966 shares during the period. Squarepoint Ops LLC owned about 0.32% of Omnicell worth $6,665,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after acquiring an additional 28,573 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Lazard Asset Management LLC boosted its position in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after acquiring an additional 737,536 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after acquiring an additional 377,883 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Omnicell by 93.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after acquiring an additional 699,925 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.
Analyst Upgrades and Downgrades
OMCL has been the topic of several analyst reports. Bank of America increased their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. JPMorgan Chase & Co. cut their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company restated an "overweight" rating and issued a $37.00 target price (up previously from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell presently has an average rating of "Moderate Buy" and an average target price of $44.83.
Read Our Latest Stock Analysis on Omnicell
Omnicell Price Performance
Omnicell stock traded up $0.14 during mid-day trading on Friday, reaching $29.97. The company had a trading volume of 127,506 shares, compared to its average volume of 565,337. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.40 billion, a P/E ratio of 111.00, a P/E/G ratio of 7.53 and a beta of 0.78. The business has a fifty day simple moving average of $30.51 and a 200 day simple moving average of $38.21.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $0.03 earnings per share. On average, equities research analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Omnicell Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
